Target intelligence / Profile preview

Cytotoxic chemotherapy (null)

Target
null
Molecular classification
Other
01

Overview

Cytotoxic chemotherapy refers to a group of drugs used primarily in cancer therapy that work by directly killing rapidly dividing cells, mainly by interfering with cellular processes such as DNA replication, mitosis, and protein synthesis. These agents include alkylating agents, antimetabolites, topoisomerase inhibitors, and microtubule inhibitors, each with a range of specific molecular targets but united by the end effect of inducing cell death through direct cytotoxic mechanisms. In addition to their direct effects, cytotoxic chemotherapies can modulate the immune system, sometimes enhancing anti-tumor immune responses but also causing broad immunosuppression. While effective in a range of malignancies, they are associated with significant toxicity due to effects on normal proliferating cells.

Other names
ChemotherapyCytotoxic drugsConventional chemotherapyAntineoplastic agents
02

Mechanism of action

DNA damage (alkylation/crosslinking, e.g., cyclophosphamide, cisplatin); Inhibition of DNA synthesis (antimetabolites, e.g., 5-FU, methotrexate); Disruption of mitosis (microtubule inhibitors, e.g., paclitaxel, vincristine); Topoisomerase inhibition (e.g., doxorubicin, etoposide); Induction of apoptosis; Immunomodulation (induction of immunogenic cell death and effects on immune cell populations)

03

Biological functions

Cell deathApoptosisInhibition of cell proliferationImmunogenic cell death
04

Disease associations

CancerAutoimmune diseasesImmunosuppression
05

Safety considerations

Myelosuppression (neutropenia, anemia, thrombocytopenia)MucositisNausea, vomitingInfertilityAlopeciaPeripheral neuropathy (for some agents)Secondary malignanciesImmunosuppression and risk of infection
06

Interacting drugs

Cyclophosphamide

6 more in the full profile.

07

Biomarkers

No universal biomarkers for response (biomarker development is ongoing, with a few gene/protein markers for sensitivity or resistance to specific agents; e.g., ERCC1 expression for platinum drugs, thymidylate synthase for 5-FU, RRM1 for gemcitabine. Biomarker use is limited and not routine for all agents.)

Beyond the preview

Go deeper on Cytotoxic chemotherapy (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytotoxic chemotherapy (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call